B. subtilis spores as mucosal adjuvants
Global Vaccines & Vaccination Summit & B2B
November 01-02, 2017 | Toronto, Canada
Veronica Donato
National University of Rosario, Argentina
Scientific Tracks Abstracts : Ann Clin Trials Vaccines Res
Abstract:
B. subtilis spores have received growing attention because of their potential in biotechnology, including vaccine development. There are only a few studies using these probiotic bacteria as a vaccine delivery system or as an adjuvant itself. For this reason, with my lab team, I decided to study B. subtilis spores as a potential candidate to solve some of the problems of current vaccines such as the need of refrigeration systems, needles and syringes and booster dose. I will present some of our data and a review of what is known about this probiotic bacteria that can help us improving the inmunization world
Biography:
She is a Postdoctoral fellow National University of Rosario. School of Biochemistry. CONICET. Molecular Microbiology Lab. Mentor: Roberto Grau, PhD C. elegans and Bacillus subtilis. Studies on host-bacteria interactions: aging, gut, inmune and nervous system. Neurobiology. PDTS38 CONICET Projects. My postdoctoral research focused on studing the microbiota effects in C. elegans gut, inmune and nervous systems. Moreover, my project studied the effects of biofilm proficiency, nitric oxide and bacterial quorum sensing molecules in C. elegans aging process
PDF HTML